Befarin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Befarin

This foundational section provides a concise overview of the nature, composition, and general action of Befarin, which is a synthetic medicinal product containing the active substance Warfarin Sodium.

Property Description
Active ingredient Warfarin Sodium
Form Oral tablet, sterile lyophilized powder (injection)
Pharmacological class Anticoagulant, Vitamin K Antagonist (VKA)
General purpose Prevention of pathological blood clot formation
Origin Synthetic, Coumarin derivative

What Type of Medication is Befarin?

Befarin is formally classified as a synthetic anticoagulant medication, a type of drug often referred to as a blood thinner. Its active ingredient, Warfarin Sodium, belongs to the Coumarin derivative group and is specifically recognized as a Vitamin K Antagonist (VKA). This classification indicates its fundamental mode of action, which involves interfering with the body's utilization of a specific nutrient to achieve its therapeutic effect, distinguishing it from other pharmacological classes of anticoagulants. As an anticoagulant, Warfarin is used to reduce the clotting ability of blood.

Composition and Pharmaceutical Form of Warfarin Sodium

The core of the medicine is the single-component substance, Warfarin Sodium, which is presented as a racemic mixture composed of both R- and S-enantiomers, a feature that influences the drug's metabolism. The drug is most commonly administered as an oral tablet for patient convenience, but it is also available as a sterile lyophilized powder for intravenous injection in certain clinical situations. This ensures that the medication can be administered reliably even when patients cannot take tablets by mouth. The tablets are produced using the active compound combined with standard, inert pharmaceutical excipients, ensuring stable and consistent delivery of the Warfarin Sodium.

General Purpose: Why is Befarin Prescribed?

The general purpose of Warfarin Sodium is to reduce the ability of the blood to clot, which helps prevent the formation of harmful blockages in the body's vascular system. By interfering with the regeneration of Vitamin K in the liver, the drug slows the production of several key clotting factors (proteins), thereby achieving its VKA effect. This action is utilized in patients requiring continuous therapy to manage the risk of clot-related events. This ultimately works to maintain smooth, uninterrupted blood flow and mitigate the overall risk associated with unwanted clot development throughout the circulatory system.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine
  2. DailyMed, National Institutes of Health

What side effects are possible with Befarin?

The official safety profile for Warfarin Sodium (Befarin) is strictly defined by regulatory documents, with the most significant risk being hemorrhage (bleeding), which is classified as a Very Common adverse reaction. This risk is highest during the starting period of therapy (within the first month) and under conditions of excessive anticoagulation.

Officially Documented Adverse Reactions by System

Adverse reactions are grouped by the physiological system affected, reflecting the full scope of potential events documented by regulatory authorities:

  • Blood and lymphatic system disorders: Hemorrhage (Very Common).
  • Skin and subcutaneous tissue disorders: Tissue necrosis (tissue death) and gangrene are serious risks, usually appearing within a few days of starting therapy. Gastrointestinal effects such as nausea, vomiting, and diarrhea are classified as Uncommon.
  • Vascular disorders: Systemic atheroemboli and cholesterol microemboli may occur, including Blue Toe Syndrome, which typically develops three to eight weeks after initiation and is classified as Very Rare.
  • Hepatobiliary disorders: Jaundice and hepatic dysfunction are listed as Rare reactions.

Serious Safety Constraints

Warfarin Sodium is formally defined as a narrow therapeutic index drug by regulators. The most critical safety constraint is the requirement for regular monitoring of the International Normalized Ratio (INR) to maintain anticoagulation status within documented safe ranges. Furthermore, specific populations, including older adults (aged 65 and older) and patients with impaired renal or hepatic function, are documented as having a greater risk of bleeding complications. The drug is associated with fetal harm and is generally contraindicated in the first and third trimesters of pregnancy.

Overdose and Emergency Response

Overdose with Befarin results in excessive anticoagulation, which is formally defined by a laboratory result showing a severely elevated International Normalized Ratio (INR), typically above 4.0. The primary and most dangerous manifestation of this condition is the risk of hemorrhage (bleeding), which may be classified as major or even fatal and can occur in any organ or tissue. Documented risks for experiencing a severe bleeding event are associated with patient age 65 or older and the presence of renal insufficiency.

It is regulatory guidance that urgent medical attention must be sought if any signs or symptoms of bleeding occur, such as unexpected pain, bruising, or severe and uncontrollable external bleeding. Patients should be instructed to report immediately to a physician if any unusual or severe bleeding is noticed.

Official management procedures for severe over-anticoagulation involve the immediate holding or discontinuation of the Befarin dose. The documented reversal agent is Vitamin K1 (Phytonadione), which is used to help restore the body's clotting ability. In cases of major or life-threatening bleeding, supportive procedures such as the administration of Fresh Frozen Plasma (FFP) or Prothrombin Complex Concentrate (PCC) are required to manage the condition. Continuous and regular INR monitoring is mandated to guide all therapeutic interventions and ensure patient stabilization.

Therapeutic Uses of Befarin

What Befarin Treats: Main Uses and Benefits

Befarin is commonly used across domains where additional symptomatic support is needed. It provides support that helps ease the overall symptom burden by contributing to improved comfort during periods of heightened symptoms. The medicine is considered relevant for easing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity.


Therapeutic Domains

Befarin is commonly used across conditions presenting with acute episodes and recurrent or episodic manifestations. It helps address symptom clusters that may become intense or disruptive, and may help patients cope more steadily with symptom fluctuations during periods of symptomatic discomfort.

“Applied in clinical settings that involve acute or unstable symptom patterns, Befarin assists with short-term symptomatic assistance when symptoms become more noticeable.”


Clinical Utility

The medicine is applied during phases of increased distress or discomfort, often used when symptoms intensify and supportive relief is needed. This use is considered relevant in addressing conditions characterized by periods of heightened symptoms, conditions involving episodic or fluctuating manifestations, and conditions where functional stability becomes affected. It offers symptomatic relief that generally helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Support for Symptom Clusters

Befarin may assist with groups of symptoms that may appear suddenly or fluctuate, interfering with daily comfort.

Eligibility and Restrictions for Use

Befarin, an anticoagulant, is primarily prescribed to reduce the risk of blood clots that can lead to serious events like stroke, heart attack, deep vein thrombosis (DVT), or pulmonary embolism (PE). It is commonly indicated for patients with conditions such as atrial fibrillation, those with mechanical or bioprosthetic heart valves, and for the treatment and prevention of DVT and PE.


However, Befarin is contraindicated in several situations where the risk of bleeding is significantly elevated. Individuals with active bleeding, a history of a major bleeding event (like a hemorrhagic stroke or recent gastrointestinal bleed), or those with uncontrolled, severe hypertension should generally not take this medication.

It is also not recommended for patients who have recently had or are planning to undergo surgery on the central nervous system (brain/spine) or eye, or those requiring a spinal puncture (e.g., an epidural). Pregnancy is a strict contraindication, as Befarin can cause serious fetal harm, including birth defects. Caution is advised for the elderly, and those with severe liver disease, kidney disease, or certain hereditary clotting deficiencies, as these conditions can affect the drug’s proper management and increase risks.

What should I know about interactions with other medicines?

Befarin Interactions with other medicines and products

Befarin (Warfarin) has a narrow therapeutic range and is subject to numerous clinically significant interactions that can profoundly affect its anticoagulant effect, leading to an increased risk of bleeding or clotting. Therefore, any change in medication, including over-the-counter products, herbal supplements, or diet, requires careful monitoring of the International Normalized Ratio (INR).

Interacting Products and Mechanisms

Many interactions are pharmacokinetic, resulting from interference with the metabolism of Befarin by Cytochrome P450 enzymes (CYP2C9 is a primary pathway). Inhibitors of this enzyme, such as Amiodarone, Fluconazole, and Sulfamethoxazole/Trimethoprim, increase Befarin levels and raise the risk of bleeding. Conversely, enzyme inducers like Rifampin or the supplement St. John's wort can decrease Befarin's effect.

Other interactions are pharmacodynamic, increasing the bleeding risk directly due to antiplatelet or ulcerogenic properties. This includes combining Befarin with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, Aspirin, and other anticoagulant or antiplatelet agents. High doses of Acetaminophen may also increase the risk.

Dietary and Substance Interactions

Dietary intake of Vitamin K, primarily found in leafy green vegetables, is a critical factor. Vitamin K reverses the action of Befarin; therefore, sudden, large changes in its consumption can destabilize the INR. The intake of alcohol should be consistent and moderate, as acute excessive consumption can also increase bleeding risk. Patients must discuss all herbal remedies, vitamins, and supplements (e.g., Garlic, Ginkgo biloba) with their healthcare provider prior to use.

Mechanism of Action

Targeting the Vitamin K Recycling Enzyme (VKORC1)

Befarin (Warfarin Sodium) works by acting as a competitive inhibitor of the enzyme Vitamin K Epoxide Reductase Complex 1 (VKORC1) in the liver . This molecular interaction blocks the necessary recycling of oxidized Vitamin K back into its active form, rapidly depleting the essential cofactor required for synthesizing functional clotting proteins.


Impairing Clotting Factor Activation

The resulting shortage of active Vitamin K prevents the crucial gamma-carboxylation of precursor clotting Factors II, VII, IX, and X. The liver releases these proteins into the bloodstream in a biologically inactive state, directly impairing the ability of the blood to form stable clots. This systemic modulation of coagulation leads to a physiological state of hypocoagulability.


Time-Delayed Systemic Effect

The maximum change in physiological coagulation parameters is delayed because the drug modulates the synthesis of new functional clotting factors. The system must wait for the existing, functional clotting factors already circulating in the blood to be naturally cleared before the inactive factors dominate, which explains the time required for the change in blood coagulability to fully manifest.

Dosage and Administration Information

How to use Befarin (Warfarin Sodium): Administration Guidelines

Befarin, which contains Warfarin Sodium, is an anticoagulant requiring highly individualized dosing managed by a healthcare professional. Standard guidelines for its use are established to ensure consistent and measurable effect.


Administration and Dosage Forms

Befarin is used for administration via two primary routes, corresponding to its available forms:

  • Oral (PO): The most common route, using scored tablets available in multiple strengths (e.g., 1 mg, 2.5 mg, 5 mg).
  • Intravenous (IV): Used in specific clinical settings via the sterile lyophilized powder form.

Standard Dosing Protocol and Frequency

The dosage of Warfarin is adjusted to maintain the blood's International Normalized Ratio (INR) within a specific target range, typically between 2.0 and 3.0.

Dosing Parameter General Guidelines
Dose Frequency Once daily
Initial Adult Dose Typically 2 mg to 5 mg once daily; lower doses recommended for older or sensitive patients.
Maintenance Dose Highly variable, generally between 2 mg and 10 mg once daily, adjusted based on INR results.

The medication must be taken at the same time every day to ensure stable blood concentration, and frequent INR testing is mandatory, especially during the initiation phase.


Practical Administration Requirements

  • Timing with Meals: Befarin tablets can be taken with food or on an empty stomach.
  • Dietary Consistency: Patients must maintain a consistent and balanced diet and should avoid making sudden changes to the intake of Vitamin K-rich foods.
  • Missed Dose: If a dose is missed, it should be taken as soon as possible on the same day; however, do not take two doses at the same time or the following day to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Befarin (Warfarin Sodium)

The evidence base for Befarin (Warfarin Sodium) is built upon decades of extensive research, including foundational randomized controlled trials (RCTs) and large-scale observational studies. This research primarily describes the patterns observed when the medication was evaluated in specific contexts related to the study of pathological blood clots.


Evidence for Use in Atrial Fibrillation (AF)

Research for this indication was conducted using major RCTs and a large volume of observational cohort studies that explored the risk of stroke and systemic embolism in patients with AF. Studies monitored key outcomes, specifically the rates of ischemic stroke and the occurrence of large systemic blood clots (thromboembolism). Research observed that the measured outcomes in studies were observed to vary depending on the quality of Warfarin management, often measured by a technical value called Time in Therapeutic Range (TTR).


Evidence for Preventing Clotting with Mechanical Heart Valves

The research base for this indication includes Clinical Trials and subsequent long-term Observational Cohort Studies. These studies were used to examine how events were monitored in patients who have received a replacement mechanical heart valve. Studies monitored the occurrence of specific events, such as valve thrombosis and stroke. Research specifically comparing Befarin against other therapeutic agents is limited, but the long-standing regulatory consensus is based on the consistent data available for Befarin in this context.


Evidence for Treating and Preventing Venous Thromboembolism (VTE)

Research explored the use of Befarin in managing and preventing recurrent blood clots (DVT and PE). Studies monitored the incidence of recurring VTE events during short-term treatment and intermediate-term prevention phases. In most trials, Befarin typically followed an initial course of injectable treatment (a process called "bridge therapy"). This means that the research does not provide full insight into its use as a standalone initial treatment, as the studies focus heavily on the transition and long-term maintenance phases.


Areas of Uncertainty and Research Gaps

While extensive, the research base contains limitations where certainty remains low. One significant gap is that the results apply only to the populations studied, and there is limited information for long-term outcomes in certain clinical contexts. Additionally, the mixed findings from genetic dosing studies indicate that the full clinical relevance of this research is still emerging, and more data are needed to confirm its long-term impact on patient outcomes.

Key Studies & References

  1. Atrial Fibrillation—Recent Key Trials on Anticoagulation (Includes ACTIVE W and SPORTIF trials on warfarin baseline data)
  2. FDA Label: WARFARIN SODIUM tablet (Includes approved indications, TTR relevance, and general context)

Frequently Asked Questions (FAQ)

Common questions about Befarin (FAQ)

Q: What is the main reason doctors prescribe Befarin?

Regulatory documents state that this medication is indicated for the treatment and prevention of blood clots, specifically for venous thrombosis, pulmonary embolism (PE), and thromboembolic complications associated with atrial fibrillation (AF). It is also indicated to reduce the risk of death and recurrent myocardial infarction (MI) after a heart attack.

Q: Is Befarin the same kind of medicine as [similar common drug name]?

Befarin (Warfarin) is classified as a Vitamin K antagonist. This means it works by interfering with the body's ability to recycle Vitamin K, which is essential for forming stable blood clots.

Q: Is Befarin safe for older adults to use?

Official documents state that age 65 and older is identified as a risk factor for bleeding complications while using this medication. The regulatory information reflects that older adults may require more frequent monitoring of their INR blood tests and careful dose adjustment.

Q: Can people with liver problems use Befarin?

Official warnings note that hepatic impairment (liver problems) is a risk factor for bleeding complications. Liver function is important because the drug is metabolized there, and impairment may increase the drug's effect.

Q: How is Befarin different from over-the-counter supplements for similar conditions?

Befarin (Warfarin) is classified as a prescription-only medication and acts as a Vitamin K antagonist, meaning it directly targets the clotting system. Supplements, herbal products, and vitamins are defined in regulatory documents as interacting products that can affect the drug's activity, and they do not carry the same regulatory classification.

Q: Do certain foods or drinks need to be avoided while using Befarin?

Official guidance describes the importance of maintaining a consistent intake of Vitamin K-rich foods and consistent, moderate alcohol consumption for stable INR levels. Regulatory information also notes that certain fruit juices, including grapefruit, cranberry, and noni juice, have been cited in case reports for potentially interacting with the medication.

Q: Can I take Befarin if I have a history of [common organ] issues?

Official warnings describe an increased risk for people with conditions like a history of bleeding, very high blood pressure, or impaired renal (kidney) or hepatic (liver) function. These factors are noted because they may increase the risk of complications while using the medication.

Q: Why do some people experience better results with Befarin than others?

The maintenance dose of Warfarin is highly individualized and is adjusted based on a person’s INR results. Official guidance notes that genetic factors, specifically related to the CYP2C9 and VKORC1 genes, can influence how the body processes the drug and may contribute to differences in individual responses.

Q: Does Befarin affect laboratory test results?

Befarin is designed to affect the body's clotting ability, and its use requires regular monitoring using the International Normalized Ratio (INR) test. The INR is a measure derived from the prothrombin time (PT) test, which measures how quickly blood clots.

Q: What are the general expectations for follow-up appointments after starting Befarin?

Official guidance requires regular monitoring of the International Normalized Ratio (INR) in all treated patients. This monitoring typically involves frequent INR determinations upon starting the medication until the level is stable, with subsequent determinations generally scheduled every one to four weeks.

Q: Is Befarin known to cause weight changes?

Adverse event reports documented in official product information have included instances of both weight gain and weight loss in some patient populations.

Q: Does Befarin interact with caffeine or energy drinks?

Caffeine is listed in regulatory tables as an inhibitor of the CYP1A2 enzyme, which is one of the pathways involved in the metabolism of one of warfarin’s active forms. It is noted in regulatory information that consultation with a healthcare professional regarding caffeine intake is important.

Q: Does Befarin affect sleep patterns?

Adverse event reports documented in official product information have included instances of insomnia (trouble sleeping) in some patient populations.

Q: How long does Befarin stay in your system after stopping?

The drug is metabolized by the liver, and its resulting inactive substances are principally excreted through the urine and bile. Because the drug modulates the synthesis of new clotting factors, the maximum anti-coagulation effect is delayed and reached within 72 to 96 hours after a dose.

Q: Is it normal to feel a change in appetite while taking Befarin?

Adverse event reports documented in official product information have included instances of anorexia, which is defined as a loss of appetite, in some patient populations.

Q: Can Befarin be used in teenagers or children?

Official guidance states that Warfarin is rarely recommended for children under 2 months of age. It is used in select pediatric patients for specific conditions, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and primary thromboprophylaxis.

Q: What kinds of medical conditions prevent someone from using Befarin?

Regulatory contraindications define specific medical conditions that prevent the use of the drug. These include pre-existing hemorrhagic tendencies or blood dyscrasias, threatened abortion, eclampsia/preeclampsia, and recent or contemplated surgery of the central nervous system or eye.

Q: Is Befarin known to interact with blood pressure medications?

Regulatory tables note that some medications used for high blood pressure are listed as interacting products. For example, diltiazem and propranolol are noted as enzyme inhibitors that can potentially increase the effect of warfarin.

Q: How long does the regulatory agency recommend taking Befarin for the initial treatment phase?

The appropriate duration of therapy is highly individualized and determined by specific factors, such as the condition being treated and the risk of bleeding. For venous thromboembolism (VTE), a minimum of 3 months of treatment is often recommended, but the maximum duration is not uniformly defined in official documents.

Q: Can Befarin cause anxiety or nervousness?

Adverse event reports documented in official product information have included instances of severe emotional lability and depression in some patient populations. These are noted as central nervous system effects of the drug.

Q: What is the risk of a severe allergic reaction to Befarin?

Regulatory information notes that emergency medical attention is required if signs of a severe allergic reaction occur. These signs may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Q: How is Befarin meant to be stored (e.g., room temperature, refrigerated)?

Official product information specifies that the tablets should be kept in a cool, dry place where the temperature stays below 30 C. The medication should also be stored away from light.

Q: Is Befarin classified as a controlled substance?

Official drug facts state clearly that Warfarin is not classified as a controlled medication by government agencies.

Q: Can I use Befarin if I have a history of seizures?

Regulatory warnings for the drug state that symptoms of a serious central nervous system (CNS) event, which are noted to require urgent attention, could include convulsions (fits), slurred speech, or loss of consciousness.

Q: Does Befarin affect vision or hearing?

Adverse event reports documented in official product information have included instances of blurred vision and lacrimation (tearing). Tinnitus (ringing in the ears) has also been reported in some patient populations.

How should Befarin be stored and disposed of?

How to Store and Dispose of Befarin

The storage of Befarin (Warfarin Sodium) must strictly follow regulatory mandates to ensure product stability and safety.

Storage Requirements

Befarin tablets must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed, to protect it from moisture and light. It is a mandatory requirement to store the medicine out of the sight and reach of children to prevent accidental ingestion.

Storage Restriction Requirement
Temperature Keep away from heat and freezing.
Container Store in original, tightly closed packaging.
Protection Protect from moisture and direct light.

Disposal Instructions

Unused or expired Befarin should be disposed of promptly using a drug take-back program. If a take-back program is unavailable, official guidelines permit disposal in household trash after mixing the medicine with an unappealing substance, such as coffee grounds, and placing the mixture in a sealed bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Befarin found in:

A-Z Index: